公开(公告)号：US20230167174A1

公开(公告)日：2023-06-01

申请号：US17934795

申请日：2022-09-23

Applicant: Novartis AG

Inventor： Verena BRAND ,  Dominik FEUERBACH ,  Fabrizio GASPARINI ,  Nathalie GEORGE ,  Eveline SCHAADT ,  Derya SHIMSHEK ,  Honnappa SRINIVAS ,  Markus WALDHUBER ,  Rainer WILCKEN

IPC: C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  C12N7/00 ,  C12N15/70

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61P25/28 ,  C12N7/00 ,  C12N15/70 ,  A61K2039/505

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US20240082215A1

公开(公告)日：2024-03-14

申请号：US18266917

申请日：2021-12-09

Applicant: Novartis AG ,  Yale University

Inventor： Fabrizio GASPARINI ,  Baltazar GOMEZ-MANCILLA ,  John KRYSTAL ,  Vincent MALATERRE ,  Stephanie O'MALLEY ,  Godfrey PEARLSON ,  Marc POTENZA

IPC: A61K31/404 ,  A61P25/30

CPC classification number: A61K31/404 ,  A61P25/30

Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.

公开(公告)号：US20250136685A1

公开(公告)日：2025-05-01

申请号：US18999104

申请日：2024-12-23

Applicant: Novartis AG

Inventor： Verena BRAND ,  Dominik FEUERBACH ,  Fabrizio GASPARINI ,  Nathalie GEORGE ,  Eveline SCHAADT ,  Derya SHIMSHEK ,  Honnappa SRINIVAS ,  Markus WALDHUBER ,  Rainer WILCKEN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61P25/28 ,  C12N7/00 ,  C12N15/70

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US20240050408A1

公开(公告)日：2024-02-15

申请号：US18266427

申请日：2021-12-09

Applicant: NOVARTIS AG

Inventor： Fabrizio GASPARINI ,  Baltazar GOMEZ-MANCILLA,

IPC: A61K31/404 ,  A61K31/55 ,  A61K31/137 ,  A61K31/551 ,  A61P25/30

CPC classification number: A61K31/404 ,  A61K31/55 ,  A61K31/137 ,  A61K31/551 ,  A61P25/30

Abstract: The invention relates to the mavoglurant, or a pharmaceutically acceptable salt thereof: in the treatment of substance use disorder, wherein the substance is an amphetamine-type stimulant; in a treatment in the reduction of substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to prevent relapse into substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to promote substance abstinence by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in the treatment of the symptoms of depression or anxiety associated with substance use disorder, wherein the substance is an amphetamine-type stimulant.

公开(公告)号：US20230270720A1

公开(公告)日：2023-08-31

申请号：US18005364

申请日：2021-07-15

Applicant: Novartis AG

Inventor： Richard Carl Elciario DOLMETSCH ,  Fabrizio GASPARINI ,  Baltazar GOMEZ-MANCILLA

IPC: A61K31/404 ,  A61P25/36

CPC classification number: A61K31/404 ,  A61P25/36

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of opioid use by an opioid use disorder patient; in preventing relapse into opioid use by an opioid use disorder patient; in the promotion of opioid abstinence by an opioid use disorder patient; in the treatment of the symptoms of depression or anxiety associated with opioid use disorder.

公开(公告)号：US20220175793A1

公开(公告)日：2022-06-09

申请号：US17310287

申请日：2020-01-28

Applicant: NOVARTIS AG

Inventor： Richard Carl Elciario DOLMETSCH ,  Fabrizio GASPARINI ,  Baltazar GOMEZ-MANCILLA

IPC: A61K31/551 ,  A61K45/06 ,  A61P25/04

Abstract: The invention relates to the use of a mGluR5 antagonist for the treatment of opioid analgesic tolerance associated with chronic opioid use in chronic pain.